-Advertisement-
  About AE   About NHM   Contact Us   Terms of Use   Copyright Info   Privacy Policy   Advertising Policies   Site Map
Ads on AE Biotech Applied
Custom Search of AE Site
spacer spacer

The Biopharmaceuticals

FDA-Approved Biopharmaceutical Drugs and Vaccines*

*Additional Biotechnology Drugs approved by the FDA through 1999 are listed.


The following biopharmaceutical agents have been approved by the Food and Drug Administration for marketing in the United States. The trademarked name is followed by the generic name of the drug in parentheses.

Acctimmune (gamma interferon)
Genentech, Inc.
Approved for use in the management of chronic granulomatous disease (December, 1990).
Activase (recombinant alteplase)
Genentech, Inc.
Approved for use in the treatment of myocardial infarction (November, 1987) and acute pulmonary embolism (June, 1990).
Adagen (adenosine deaminase)
Enzon, Inc.
Approved for use in the treatment of infants and children with severe immunodeficiency (March, 1990).
Alferon N
Interferon Sciences, Inc.
Approved for use in treating genital warts (October, 1989).
Betaseron (recombinant interferon beta 1-B)
Berlex Laboratories/Chiron Corp.
Approved for use in the management of relapsing, remitting multiple sclerosis (August, 1993).
Ceredase (alglucerase)
Genzyme Corp.
Approved for use in treating Type 1 Gaucher's disease (April, 1991).
Cerezyme (imiglucerase)
Genzyme Corp.
Approved for use in treating Type 1 Gaucher's disease (June, 1994).
Engerix-B
SmithKline Beecham
Approved for use as a hepatitis B vaccine (September, 1989).
EPOGEN (epoetin alfa)
Amgen Ltd.
Approved for use in treating anemia associated with chronic renal failure and anemia in Retrovir-treated, HIV-infected patients (June, 1989).
Humatrope (somatropin)
Eli Lilly & Co.
Approved for treating human growth hormone deficiency in children (March, 1987).
Humulin (recombinant human insulin)
Eli Lilly & Co.
Approved for the treatment of diabetes (October, 1982).
Intron A (alpha-interferon)
Schering-Plough Corp.
Approved for the treatment of hairy cell leukemia (June, 1986), genital warts (June, 1988), AIDS-related Kaposi's sarcoma (November, 1988), non-A, non-B hepatitis (February, 1991), and hepatitis B (July, 1992).
KoGENate (antihemophiliac factor)
Miles, Inc.
Approved for use in the treatment of hemophilia A (February, 1993).
Leukine (yeast-derived GM-CSF)
Immunex Corp.
Approved for use in autologous bone marrow transplantation (March, 1991).
Neupogen
Amgen Ltd.
Approved for use in treating cheomtherapy-induced neutropenia (February, 1991) and bone marrow transplant-associated neutropenia (June, 1994).
Oncaspar (pegaspargase)
Enzone/Rhone-Poulenc Rorer
Approved for use in treating acute lymphoblastic leukemia (February, 1994).
Orthoclone OKT 3
Ortho Biotech
Approved for use in reversal of acute kidney transplant rejection (June, 1986).
Procrit (epoetin alfa)
Ortho Biotech
Approved for use in the treatment of anemia associated with chronic renal failure (December, 1990) and anemia in Retrovir-treated, HIV-infected patients and chemotherapy-associated anemia (April, 1993).
Proleukin, IL-2
Chiron Corp.
Approved for the treatment of kidney (renal) carcinoma (May, 1992).
Protropin (somatrem)
Genentech, Inc.
Approved for treating human growth hormone deficiency in children (May, 1985).
Pulmozyme (DNase)
Genentech, Inc.
Approved for use in the management of cystic fibrosis (December, 1993).
Recombinate rAHF (recombinant antihemophiliac factor)
Baxter Healthcare
Recombinate rAHF is the recombinant version of blood clotting factor VIII, and it has been approved for the treatment of hemophilia A (December, 1992).
Recombivax HB
Merck & Co.
Approved as a hepatitis B prevention vaccine (July, 1986).
Roferon-A (recombinant alfa-interferon)
Hoffman-La Roche
Approved for the treatment of hairy cell leukemia (June, 1986) and AIDS-related Kaposi's sarcoma (November, 1988).


Biotech Applied Index


About Biotech Index


 
Custom Search on the AE Site

 

-Advertisement-